Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of venglustat in rapidly progressive ADPKD
NL-OMON51229Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of venglustat in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Sanofi. Primary endpoint: Percent change in total kidney volume. Started May 2021; status: completed.
02
Drugs
venglustat
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON51229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51229.